Whether your test was prescribed by a physician or healthcare provider, MOMS can help connect you with conveniently located medical access point locations.
Click here for instant access to lab testing sites and specialists.
Select Morningstar Laboratories as Lab Client/Provider.
We believe the current standard of care fails to accurately detect vascular disease.
- Heart disease is the leading cause of death in the US and for most people, the first sign of heart disease is a heart attack.
- 70% of heart attacks are caused by unstable cardiac lesion ruptures.
- When the lesions become inflamed, they are prone to rupture causing a blood clot which blocks blood flow to the heart resulting in a heart attack.
- 80% of premature deaths due to vascular disease are preventable with early diagnosis, management of risk factors, and lifestyle modification.
Advantages of SmartVascular Dx:
- A serum blood test we believe detects the risk of potential heart attacks and strokes of a vulnerable patient within the next 5 years.
- This diagnostic test assesses vascular health by measuring protein biomarkers that indicate inflammation in arterial lining that can lead to heart attacks and strokes.
- The test was developed through a series of longitudinal outcome-based studies with multiple institutions over a 15-year period of collaborative research representing over 40,000 patients.
- SmartVascular Dx was independently validated at the National Institute of Health (NIH) and the National Heart, Lung, and Blood Institute (NHLBI) in the Multi-Ethnic Study of Atherosclerosis (MESA).
Cross DS, McCarty CA, Hytopoulos E, et al. (2012) Coronary risk assessment among intermediate risk patients using a clinical and biomarker based algorithm developed and validated in two population cohorts. CMRO Vol 28 – Issue 11
Younus M, Fan W, Harrington D, et al. (2019) Usefulness of a Coronary Artery Disease Predictive Algorithm to Predict Global Risk for Cardiovascular Disease and Acute Coronary Syndrome. Am J Cardiol 123(5):769-775
Hytopoulos E, Lee ML, Beggs M, et al. (2014) Cost effectiveness analysis of a next generation risk assessment score for cardiovascular disease. J Med Econ 17(2):132-41